Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eisai, Orexigen, Duke University endocrine news

OREX and the university settled a dispute with Eisai over IP related to the use of zonisamide

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE